Premium
Sumatriptan ‐ Nonresponders: A Survey in 366 Migraine Patients
Author(s) -
Visser WH,
Vriend RHM,
Jaspers NHWM,
Ferrari MD
Publication year - 1996
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1046/j.1526-4610.1996.3608471.x
Subject(s) - sumatriptan , migraine , medicine , photophobia , vomiting , anesthesia , nausea , phonophobia , oral administration , surgery , aura , agonist , receptor
Sumatriptan, notably after subcutaneous administration, is highly effective in the acute treatment of migraine in the majority of patients. The response is consistent within patients and over time. To determine risk factors for nonresponse to sumatriptan, we compared clinical characteristics. In responders and nonresponders and, within patients, between attacks with and without response. We found no differences at the strict level of significance (P<0.001 because of multiple comparisons), but only tendencies for differences (0.001